In terms of the relationship between Src activation and the response to targeted therapy, one study which involved 57 BC patients showed that tumors with a high level of phosphorylated Src (pSrc) had a poor clinical response and more aggressive disease after trastuzumab therapy. The gene discussed is SRC; the disease is breast cancer.